1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol has been researched along with hydralazine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (87.50) | 18.7374 |
| 1990's | 1 (12.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Bowler, J; Bremner, JC; Stratford, IJ | 1 |
| Adams, GE; Godden, J; Howells, N; Stratford, IJ | 1 |
| Adams, GE; Cole, S; Stratford, IJ | 1 |
| Cole, S; Robbins, L | 1 |
| Chaplin, DJ | 2 |
| Chaplin, DJ; Horsman, MR; Overgaard, J | 1 |
| Acker, B; Chaplin, DJ | 1 |
8 other study(ies) available for 1-(2-nitro-1-imidazolyl)-3-aziridino-2-propanol and hydralazine
| Article | Year |
|---|---|
Bioreductive drugs and the selective induction of tumour hypoxia.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Constriction; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Mitomycin; Mitomycins; Radiation-Sensitizing Agents; Sarcoma, Experimental; Tirapazamine; Triazines | 1990 |
Induction of tumour hypoxia post-irradiation: a method for increasing the sensitizing efficiency of misonidazole and RSU 1069 in vivo.
Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Oxygen; Radiation-Sensitizing Agents | 1989 |
Manipulation of radiobiological hypoxia in a human melanoma xenograft to exploit the bioreductive cytotoxicity of RSU-1069.
Topics: Animals; Cell Hypoxia; Combined Modality Therapy; Constriction; Female; Hydralazine; Melanoma; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Radiation-Sensitizing Agents; Transplantation, Heterologous | 1989 |
Manipulation of oxygenation in a human tumour xenograft with BW12C or hydralazine: effects on responses to radiation and to the bioreductive cytotoxicity of misonidazole or RSU-1069.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzaldehydes; Colonic Neoplasms; Combined Modality Therapy; Female; Humans; Hydralazine; Mice; Mice, Nude; Misonidazole; Neoplasm Transplantation; Oxidation-Reduction; Oxygen; Radiation-Sensitizing Agents; Radiotherapy; Transplantation, Heterologous | 1989 |
Hydralazine-induced tumor hypoxia: a potential target for cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Aziridines; Drug Synergism; Female; Hydralazine; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; Misonidazole; Mitomycins; Neoplasms, Experimental; Regional Blood Flow | 1989 |
The interaction between RSU-1069, hydralazine and hyperthermia in a C3H mammary carcinoma as assessed by tumour growth delay.
Topics: Animals; Combined Modality Therapy; Female; Hydralazine; Hyperthermia, Induced; Male; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Mice, Inbred DBA; Misonidazole | 1988 |
Postirradiation modification of tumor blood flow: a method to increase the effectiveness of chemical radiosensitizers.
Topics: Animals; Cell Survival; Combined Modality Therapy; Female; Hydralazine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Misonidazole; Radiation-Sensitizing Agents; Regional Blood Flow; Vasodilator Agents | 1988 |
The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.
Topics: Animals; Cell Survival; Cells, Cultured; Female; Hydralazine; Lung Neoplasms; Mice; Mice, Inbred C57BL; Misonidazole; Radiation-Sensitizing Agents | 1987 |